IC
CSCI

Ikarian Capital’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Ikarian Capital’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,174
Closed -$94K – 214
2020
Q2 		$94K Hold
1,174
– – 0.01% 155
2020
Q1 		$60K Hold
1,174
– – ﹤0.01% 149
2019
Q4 		$107K Buy
+1,174
New +$109K 0.02% 107

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wedbush Securities
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Federation des caisses Desjardins du Quebec
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DWM
Dorchester Wealth Management Montreal, Quebec, Canada $501M AUM 16.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RFA
Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return

Ikarian Capital's CSCI Position: Q3 2020 in Review

Ikarian Capital sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2020, closing a stake of 1,174 shares — an estimated $94K sold.

Ikarian Capital first reported a position in CSCI in Q4 2019 and held it in 3 quarters. The position peaked at $107K in Q4 2019. 16 funds tracked by Wall St. Rank hold CSCI as of Q3 2020.

  • Ikarian Capital reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Ikarian Capital sold 1,174 COSCIENS Biopharma Inc. Common Stock shares in Q3 2020, an estimated $94K.
  • Ikarian Capital first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Ikarian Capital's COSCIENS Biopharma Inc. Common Stock position peaked at $107K in Q4 2019.
  • 16 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2020.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.